The Future of Botox – PurTox and Xeomin
Friday, January 6th, 2012Future Non-Surgical Facelift Options: PurTox and Xeomin
Liquid facelifts, a non-surgical option ideal for those who don’t have a lot of wrinkles or sagging skin, has been a huge commodity for plastic surgeons looking to provide a minimally invasive anti-aging procedure. FDA-approved injectables include Botox, Collagen and the recently approved Dysport. All have great similarities and great differences, depending on your preference. However, if these options aren’t enough, spectacular advances in cosmetic surgery education and technology have given way to improved options for great face lift alternatives.
Recently featured in New Beauty Magazine, Xeomin and PurTox are said to be the newest faces of injectable treatments. Let’s take a better look at both, which are anticipating FDA-approval as soon as 2010.
PurTox has had very positive reviews in clinical trials, that, like Botox, is a prepared botulinum type A neurotoxin. PurTox is essentially touted as the purer form of Botox, and therefore believed to produce more natural and longer lasting results than the latter competitor. PurTox works by blocking muscle activity in the face, preventing the appearance of fine lines and wrinkles. A normal procedure can be performed in 30 minutes or less and is believed to cost from $500-$2500 per treatment, similar to Botox and Dysport. Like Botox and Dysport, PurTox’s side effects include the possibility of ptosis (eyelid drooping), swelling, bruising and irritation or redness at the injection site.
Xeomin is the one of the newest green options available among the current line of injectables. A prepared botulinum toxin that’s already available for use in Europe, Xeomin lacks complexing proteins removed during a purification process. These proteins are believed to heighten your immune system’s response to the substance and decrease antibody development. In addition, Xeomin remains stable at room temperature for three years, removing the need for refrigeration (which is why it’s considered a green option). Xeomin is not currently FDA-approved but awaiting approval after it’s completion of clinical testing in the United States. Xeomin is also used to treat Blepharospasm, a condition characterized by involuntary closure of the eyelids, and other conditions.